Analysts Weigh EMDAC Vote on Late-Stage Obesity Drugs
As the dust settled after the two-day Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting ended with a 17-6 vote in favor of requiring large cardiovascular outcomes trials (CVOTs) for all obesity drugs, regardless of cardiovascular risk or signal, analysts began scrambling to gauge whether the recommendations will affect the upcoming FDA decisions for Vivus Inc.'s Qnexa and Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST